07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , Apr 21, 2016 |  BC Innovations  |  Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as Phase...
07:00 , Oct 16, 2014 |  BC Innovations  |  Targets & Mechanisms

Alnylam interrupts preeclampsia

Preeclampsia often involves overactivation of the renin-angiotensin system that regulates blood pressure, but inhibiting the pathway is not possible because it would be toxic to the fetus. Alnylam Pharmaceuticals Inc. has developed an siRNA conjugate...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In a rat model of preeclampsia, subcutaneous ALN-AGT led to >90% knockdown of maternal angiotensinogen (AGT) in the liver with no detectable evidence of fetal drug exposure. ALN-AGT also significantly reduced mean arterial blood pressure...